Craft

Vasomedical

Stock Price

$0.2

2024-10-29

Market Capitalization

$26.3 M

2024-10-29

Revenue

$89.1 M

FY, 2025

Vasomedical Summary

Company Summary

Overview
Vasomedical is engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP® ) therapy systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system diseases that is cleared by the FDA and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance, and a staff training and maintenance programs designed to provide optimal patient outcomes. The Company also provides other non-invasive medical equipment including a full range of Biox™ ECG Holter monitors recorders and ambulatory blood pressure monitors.
Type
Public
Status
Active
Founded
1994
HQ
Plainview, NY, US | view all locations
Website
http://www.vasomedical.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Operating MetricsView all

Patents (US)

11

FY, 2016

Patents (Foreign)

13

FY, 2016

Conveyancing Completions

8

FY, 2016

LocationsView all

2 locations detected

  • Plainview, NY HQ

    United States

    137 Commercial St #200

  • New York, NY

    United States

    111 John St #1702

Vasomedical Financials

Summary Financials

Revenue (FY, 2025)
$89.1M
Gross profit (FY, 2025)
$54.7M
Cash (Q1, 2026)
$22.0M
Enterprise value
($5.4M)

Footer menu